Merck Sharp & Dohme (MRK) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Merck Sharp & Dohme, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track MRK live on Mooboard →

Next 30 days1

  • Oct 22, 2026
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Belzutifan · Phase 1 / Phase 2 · Renal Cell Carcinoma
    NCT05468697: A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024). Primary completion 2026-10-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days3

  • Oct 28, 2026
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Belzutifan · Phase 3 · Carcinoma, Renal Cell
    NCT05239728: A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022). Primary completion 2026-10-28 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 6, 2026
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    pembrolizumab · Phase 2 · Hodgkin Lymphoma
    NCT03407144: Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667). Primary completion 2026-11-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 20, 2026
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Pembrolizumab · Phase 3 · Endometrial Neoplasms
    NCT04634877: Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Primary completion 2026-11-20 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later21

  • Jan 4, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Sacituzumab tirumotecan · Phase 3 · Gastroesophageal Cancer
    NCT06356311: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015). Primary completion 2027-01-04 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 12, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Sacituzumab Govitecan · Phase 3 · Carcinoma, Non-Small-Cell Lung
    NCT05609968: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46). Primary completion 2027-01-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 31, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Pembrolizumab · Phase 3 · Urinary Bladder Neoplasms
    NCT04241185: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992). Primary completion 2027-01-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 22, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Pembrolizumab · Phase 2 · Neoplasm Malignant
    NCT04976634: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016). Primary completion 2027-03-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 31, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Posaconazole IV 6 mg/kg · Phase 2 · Invasive Fungal Infection
    NCT04665037: Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127). Primary completion 2027-03-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 23, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Pembrolizumab · Phase 1 / Phase 2 · Bladder Cancer
    NCT06305767: A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005). Primary completion 2027-04-23 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 4, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    pembrolizumab · Phase 2 · Advanced Cancer; Anal Carcinoma
    NCT02628067: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158). Primary completion 2027-05-04 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 5, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Belzutifan · Phase 2 · Metastatic Breast Cancer
    NCT06428396: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029). Primary completion 2027-05-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 5, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Pembrolizumab · Phase 3 · Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
    NCT04380636: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012). Primary completion 2027-05-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 10, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Sacituzumab tirumotecan · Phase 3 · Non-small Cell Lung Cancer (NSCLC)
    NCT06074588: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004). Primary completion 2027-05-10 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 19, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Nemtabrutinib · Phase 3 · Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    NCT05624554: A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008). Primary completion 2027-05-19 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 27, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    pembrolizumab · Phase 3 · Endometrial Neoplasms
    NCT05173987: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15). Primary completion 2027-05-27 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Coformulated favezelimab/pembrolizumab · Phase 1 / Phase 2 · Metastatic Urothelial Carcinoma; Urothelial Neoplasms
    NCT05845814: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04). Primary completion 2027-05-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 11, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Paclitaxel · Phase 1 / Phase 2 · Esophageal Squamous Cell Carcinoma
    NCT05319730: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B). Primary completion 2027-06-11 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 12, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    I-DXd · Phase 1 / Phase 2 · Oesophageal Squamous Cell Carcinoma
    NCT07405151: A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F). Primary completion 2027-06-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 15, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Tulisokibart · Phase 2 · Radiographic Axial Spondyloarthritis
    NCT07133633: A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013). Primary completion 2027-06-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 24, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Suvorexant · Phase 3 · Insomnia
    NCT06655883: A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098). Primary completion 2027-06-24 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 11, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Sacituzumab tirumotecan · Phase 3 · Breast Neoplasms
    NCT06312176: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010). Primary completion 2027-07-11 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 22, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    MK-8527 · Phase 3 · Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
    NCT07044297: A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011). Primary completion 2027-07-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 30, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    Bomedemstat · Phase 3 · Essential Thrombocythemia
    NCT06079879: A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006). Primary completion 2027-07-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 10, 2027
    Merck Sharp & Dohme(MRK)Phase 2/3 readout
    ISL · Phase 2 · Human Immunodeficiency Virus Type 1 (HIV-1) Infection
    NCT06891066: A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060). Primary completion 2027-08-10 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

How Merck Sharp & Dohme has moved — past-year price reactions

How binary is MRK? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
1
±10% days
30.6%
annualized vol
249
trading days
Largest single-day moves
  • +12.6%2026-08-19no matched headline
  • +7.4%2025-10-01no matched headline
  • +6.8%2025-09-30no matched headline
  • +5.6%2026-05-22no matched headline
  • +5.2%2025-11-25no matched headline
  • +4.8%2026-06-04no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Merck Sharp & Dohme — active clinical pipeline

Merck Sharp & Dohme's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

75 assets172 programsPh1 29Ph2 67Ph3 74· 2 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceCardiovascularInfectiousOphthalmologyOther
PembrolizumabOncology · PD-1
Phase 2
Advanced CancerBladder CancerCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell (2)Colorectal CancerEsophageal Squamous Cell CarcinomaGastroesophageal JunctionHodgkin LymphomaMalignant NeoplasmNeoplasm MalignantNon-small Cell Lung Cancer
Phase 3
Bladder CancerBreast NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell (2)Cervical CancerColorectal NeoplasmsEndometrial CancerEndometrial Neoplasms (2)High-risk Non-muscle Invasive Bladder CancerLung NeoplasmsMelanoma (2)Non-small Cell Lung Cancer (2)Solid TumorsTriple-Negative Breast CancerUrinary Bladder Cancer, Muscle-invasive
Sacituzumab tirumotecanOncology
Phase 1
Non-small Cell Lung Cancer
Phase 2
Colorectal CancerMetastatic Urothelial CarcinomaNon-Muscle Invasive Bladder Cancer
Phase 3
Bladder CancerBreast NeoplasmsCervical CancerEndometrial CancerGastroesophageal CancerNon Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC) (3)Ovarian CancerOvarian NeoplasmsTriple Negative Breast Neoplasms
BelzutifanOncology · HIF-2α
Phase 1
Renal Cell Carcinoma
Phase 2
Carcinoma, Renal CellMalignant NeoplasmMetastatic Breast CancerPheochromocytoma/ParagangliomaRenal Cell Carcinoma (2)
Phase 3
Carcinoma, Renal Cell (4)Von Hippel-Lindau Disease
Zilovertamab vedotinOncology
Phase 2
B-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaLymphoma, Large B-Cell, Diffuse (DLBCL)Urothelial Carcinoma
Phase 3
Diffuse Large B-Cell LymphomaDLBCL
Intismeran autogeneOncology
Phase 2
Malignant MelanomaRenal Cell CarcinomaUrinary Bladder Neoplasms
Phase 3
MelanomaNon-small Cell Lung Cancer
CalderasibOncology
Phase 1
Advanced Solid Tumors
Phase 2
Neoplasm Malignant
Phase 3
Colon AdenocarcinomaNon-small Cell Lung Cancer (4)
Enlicitide DecanoateMetabolic
Phase 3
ArteriosclerosisHeterozygous Familial Hypercholesterolemia (HeFH)HypercholesterolemiaHyperlipidemia
MK-1045Oncology
Phase 1
Systemic Lupus Erythematosus
Phase 2
Lymphoma, Non-Hodgkin
Phase 3
B-cell Acute Lymphoblastic LeukemiaFollicular Lymphoma
NemtabrutinibOncology
Phase 1
Hematological MalignanciesSevere Renal Impairment
Phase 2
Lymphoma, B-Cell
Phase 3
Chronic Lymphocytic Leukemia (2)
OpevesostatOncology
Phase 2
Malignant NeoplasmProstatic Neoplasms, Castration-Resistant
Phase 3
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostate Cancer Metastatic
Patritumab deruxtecanOncology · HER3 ADC
Phase 2
Breast Neoplasms (2)Gastrointestinal CancerMalignant Neoplasm
Phase 3
Breast Neoplasms
Pembrolizumab (+) Berahyaluronidase alfaOncology
Phase 2
Classical Hodgkin Lymphoma RecurrentNon-Small Cell Lung CancerSquamous Cell Carcinoma
Phase 3
Lung Cancer
TulisokibartAutoimmune
Phase 2
Arthritis, RheumatoidHidradenitis SuppurativaRadiographic Axial Spondyloarthritis
Phase 3
Crohn Disease
MK-8527Infectious
Phase 1
Human Immunodeficiency Virus (HIV)Infectious
Phase 3
Human Immunodeficiency Virus (HIV) (2)
Pembrolizumab 200 mgOncology · PD-1
Phase 2
Metastatic Castration-Resistant Prostate Cancer
Phase 3
Head and Neck NeoplasmsSmall Cell Lung Cancer
SotaterceptCardiovascular · activin A
Phase 2
Hypertension, PulmonaryPulmonary Arterial Hypertension (3)
Phase 3
Pulmonary Arterial Hypertension
BomedemstatCardiovascular · KDM1A
Phase 3
Essential ThrombocythemiaThrombocythemia, Essential
DOR/ISLInfectious
Phase 3
HIV InfectionHIV-1 Infection (2)
EnlicitideMetabolic
Phase 1
Metabolic
Phase 3
Hyperlipidemia
Ifinatamab DeruxtecanOncology
Phase 2
Malignant Neoplasm
Phase 3
Prostate Cancer
ISLInfectious
Phase 2
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Phase 3
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
IV TulisokibartAutoimmune
Phase 3
Crohn's DiseaseUlcerative Colitis
R-DXDOncology
Phase 2
Lung Neoplasm
Phase 3
Ovarian Cancer (2)
9vHPV vaccineInfectious
Phase 3
Papillomavirus Infections (3)
ARTInfectious
Phase 3
HIV-1 Infection
IntismeranOncology
Phase 3
Non-small Cell Lung Cancer
MK-8591AInfectious
Phase 3
HIV-1 Infection
MK-8748Ophthalmology
Phase 3
Diabetic Retinopathy (2)
MolnupiravirInfectious
Phase 3
Coronavirus Disease (COVID-19)
Pembrolizumab (K)Oncology · PD-1
Phase 3
Breast Cancer
Pembrolizumab Formulated with Berahyaluronidase AlfaOncology
Phase 3
Metastatic Non-small Cell Lung Cancer (2)
Pembrolizumab SCOncology
Phase 3
Non-Small Cell Lung Cancer
Pembrolizumab/Vibostolimab Co-FormulationOncology
Phase 3
Small Cell Lung Carcinoma
Sac-TMTOncology
Phase 3
Bladder Cancer
Sacituzumab GovitecanOncology · TROP2 ADC
Phase 3
Carcinoma, Non-Small-Cell Lung
V181Infectious
Phase 3
Infectious
V503Infectious
Phase 3
Papillomavirus Infections (2)
Vericiguat tabletCardiovascular
Phase 3
Heart Failure
GocatamigOncology
Phase 2
Small Cell Lung CancerSmall Cell Lung Cancer Extensive Stage
MK-2010Oncology
Phase 2
Advanced Solid TumorsMalignant Neoplam
MK-7262Other
Phase 1
Healthy volunteers
Phase 2
Lipoprotein(a)
Coformulated favezelimab/pembrolizumabOncology
Phase 2
Metastatic Urothelial Carcinoma
coformulation pembrolizumab/quavonlimabOncology
Phase 2
Small Cell Lung Carcinoma
DoravirineInfectious
Phase 2
Human Immunodeficiency Virus (HIV) Infection
FrespaciguatCardiovascular
Phase 2
Pulmonary Hypertension
I-DXdOncology
Phase 2
Oesophageal Squamous Cell Carcinoma
MiransertibOther · AKT2
Phase 2
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
MK-1084Oncology
Phase 2
Lung Neoplasm Malignant
MK-2214Neuroscience
Phase 2
Early Alzheimer's Disease
MK-3120Oncology
Phase 2
Bladder Cancer
MK-8690Autoimmune
Phase 2
Colitis Ulcerative
OlaparibOncology · PARP
Phase 2
Advanced Solid Neoplasms
PaclitaxelOncology · tubulin
Phase 2
Esophageal Squamous Cell Carcinoma
Posaconazole IV 6 mg/kgInfectious
Phase 2
Invasive Fungal Infection
Raludotatug DeruxtecanOncology
Phase 2
Carcinoma, Non-Small-Cell Lung
Raludotatug Deruxtecan (R-DXd)Oncology
Phase 2
Gastrointestinal Cancer
RamucirumabOther · VEGFR2
Phase 2
Gastroesophageal Junction
UlonivirineOther
Phase 1
Healthy volunteersHepatic Insufficiency
GARDASIL®9 (G9)Other
Phase 1
Healthy volunteers
LetermovirOther · TRM1
Phase 1
Cytomegalovirus Prophylaxis
MK-0472Oncology
Phase 1
Metastatic Solid Tumors
MK-0616AOther
Phase 1
Healthy volunteers
MK-1403 formulation (FM) 1 + additiveOther
Phase 1
Healthy volunteers
MK-1484Oncology
Phase 1
Advanced or Metastatic Solid Tumors
MK-4082Other
Phase 1
Healthy volunteers
MK-4082 Formulation 1 (F1)Metabolic
Phase 1
Metabolic
MK-4716Oncology
Phase 1
Malignant Neoplasm
MK-4884Oncology
Phase 1
Malignant Neoplasm
MK-8294Oncology
Phase 1
Metastatic Neoplasm
RosuvastatinOther
Phase 1
Healthy volunteers
Tulisokibart Form 1Other
Phase 1
Healthy volunteers
V118C (Stage 1)Infectious
Phase 1
Pneumococcal Infection
V132 Formulation 1Other
Phase 1
Healthy volunteers
V350AOther
Phase 1
Healthy volunteers
V540DOther
Phase 1
Healthy volunteers

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.